The Phase III SOPHIA clinical trial is evaluating  whether margetuximab (MacroGenics) plus chemotherapy has longer progression free survival and overall survival than patients treated with trastuzumab (Herceptin/Roche) plus chemotherapy. Dr. Hope S. Rugo of University...